Vaccine adjuvant discovery program
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93024C00021
- Awardee
-
Institut De Formulation DES Vaccins (Ch) SA UEI N773KSZMJA78
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,563,776
Award facts
- Opportunity
-
- Vaccine adjuvant discovery program Pre-Solicitation · 75N93022R00022 · Posted Dec 5, 2022
- Contract value 17% obligated
-
- $1,563,776.00 Current, with exercised options
- $9,189,961.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 13 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Switzerland
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,563,776 |
About this award
This federal contract award, valued at $9,189,961.00, was granted to Institut De Formulation DES Vaccins (Ch) SA, operating as Vaccine Formulation Institute (Ch) LTD, a for-profit limited liability company based in Switzerland. The contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, for the Vaccine Adjuvant Discovery Program. This five-year definitive contract, running from September 2024 to April 2029, aims to identify and characterize novel, effective, and safe vaccine adjuvants through a multi-step research process. The contract does not have a set-aside designation, indicating the institute's competitive standing in the field of vaccine development and adjuvant discovery. The institute has also been awarded a separate $4,937,118.00 contract by NIAID for the advanced development of a liposome-based saponin-containing adjuvant for use in pan-sarbecovirus vaccines.
Quick answers
Who was awarded contract 75N93024C00021?
75N93024C00021 was awarded to Institut De Formulation DES Vaccins (Ch) SA by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 30, 2024.
How much is contract 75N93024C00021 worth?
The government has obligated $1,563,776 on 75N93024C00021. Its potential value, with all options, is $9,189,961.
Was contract 75N93024C00021 competed?
The extent of competition for 75N93024C00021 was full and open competition. The government received 13 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award